2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS

2CDA 在复发/缓解多发性硬化症中的作用

• 批准号: 6279297
• 负责人: JACK C SIPE
• 金额: $ 2.73万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279297
• 关键词: chlorodeoxyadenosine; clinical research; clinical trials; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; magnetic resonance imaging; multiple sclerosis; nervous system disorder chemotherapy; relapse /recurrence

Multiple sclerosis (MS) is a progressive neurologic disorder that is likely to have an autoimmune basis. We have been testing the safety and efficacy of cladribine (2-CdA) as a treatment for MS. Other current treatments are unsatisfactory, with Beta Interferon and Copaxone having a partial effect on relapses in MS. We have completed treatment trials in chronic progressive MS (subproject #220) and have shown that cladribine, an immunosuppressive agent, retards the progression of the disease for two years or longer. A double-blind, placebo-controlled clinical trial of cladribine in relapsing remitting MS has just been completed. The results indicate marked suppression of MRI-enhancing brain lesions in the cladribine treated group and significant reduction in both severity and frequency of clinical relapses. There was no significant toxicity or side effects of subcutaneously administered cladribine at the doses used in this study.

多发性硬化症（MS）是一种进行性神经系统疾病，是 可能具有自身免疫性基础。 我们一直在测试安全性和 甲别宾（2-CDA）作为MS的治疗方法。 其他电流 治疗不令人满意，beta Interferon和Copaxone具有 对MS复发的部分影响。 我们已经完成了治疗试验 在慢性渐进式MS（第220号子标记）中，已经表明 克拉德替宾是一种免疫抑制剂，降低了 疾病两年或更长时间。 双盲，安慰剂对照 甲别宾的临床试验在复发中恢复MS 完全的。 结果表明明显抑制了MRI增强 甲别宾治疗组中的脑病变和显着降低 在临床复发的严重程度和频率下。 没有 皮下给药的显着毒性或副作用 克拉丁替比以本研究使用的剂量。